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Purpose: To describe the clinical characteristics of idiopathic juxtafoveal telangiectasis (IJT) in Koreans.
Methods: Medical records of 16 patients with IJT were analyzed during the period from 1997 to 2009. Diagnosis was 
based on biomicrosopic and fluorescein angiographic findings and the group was determined according to the 
Gass and Blodi classification.
Results: We analyzed eight patients in group 1A (50%), two in group 1B (12.5%), and six in group 2A (37.5%). 
Diverse treatment modalities, such as macular laser photocoagulation, photodynamic therapy, intravitreal anti-
angiogenic agent, and steroid injection, were applied for macular edema in nine eyes; however, only two eyes 
showed visual improvement.
Conculsions: In this case series, group 1A was the most common. For macular edema related to IJT, current treat-
ment strategies had no consistent effect.   
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In 1982, Gass and Oyakawa [1] defined idiopathic juxta-
foveal telangiectasis (IJT) as a unilateral or bilateral devel-
opmental retinal vascular abnormality associated with in-
competence and ectasia of foveal and parafoveal capillaries. 
Classification and staging of IJT was based on clinical and 
fluorescein angiographic findings. This classification was 
later updated by Gass and Blodi [2]. The pathophysiology 
of IJT is still unknown, although the cause of visual loss in 
IJT is associated with macular edema [1,2]. Several treat-
ment modalities such as laser photocoagulation [3,4], pho-
todynamic therapy (PDT) [5,6], and intravitreal injection of 
triamcinolone acetonide [7,8] or bevacizumab [9-12] have 
been tested for the treatment of macular edema in IJT. To 
date, only one study has investigated IJT in Korean patients: 
Chang et al. [3] reported that the group 1B subtype was the 
most common and that argon laser photocoagulation was an 
effective treatment for macular edema in IJT. In this study, 
we identified the clinical characteristics of IJT in Koreans.
Materials and Methods
We reviewed the medical records of 16 IJT patients (22 
affected eyes) presenting to the Samsung Medical Center 
between 1997 and 2009. Patients with secondary juxtafo-
veal telangiectasis caused by retinal venous obstruction, ir-
radiation, and intraocular inflammation were excluded from 
this study. All patients provided a detailed medical and ocu-
lar history and underwent a complete eye examination in-
cluding slit-lamp biomicroscopy, fundus photography, and 
fluorescein angiography. Clinical features analyzed included 
age at diagnosis, gender, laterality, best corrected visual 
acuity (BCVA), systemic disease, type of treatment, and 
classification of the disease according to Gass and Blodi [2] 
(Table 1).
Results 
Of the 16 study patients, eight had group 1A disease, two 
had group 1B, and six had group 2A. 
Group 1A
Eight patients (six males and two females) were classified 
as group 1A. Patients ranged in age from 11 to 66 years Korean J Ophthalmol Vol.25, No.4, 2011
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Table 1. Demographic and clinical information for 16 patients with idiopathic juxtafoveal retinal telangiectasis
Group Cases no Age Sex Involved eye Systemic disease Treatment VApre VApost Follow up (mon)
1A  1 11 M Right LP 0.5 0.3 11
 3 50 M Left DM Observation 0.7 0.7   2
 4 63 M Left DM LP  0.05  0.03 15
 7 57 M Left IVB,  LP 0.7 0.7 62
  9 66 M Left IVB, LP 0.3 0.5  3
10 62 F Right DM, HTN Observation 0.7 0.7  2
12 53 M Right IVB, LP 0.5 0.5  4
13 51 F Left IVB, LP 0.3 0.3  8
1B  2 59 F Left IVTA,  vitrectomy 0.4  0.15 56
 6 55 M Right PDT 0.5 0.9 48
2A  5 59 F Both DM Observation 0.7/0/7 0.7/0.7 10
 8 53 F Both PDT,  LP 1.0/0.6 1.0/0.6 40
11 38 F Both Observation 1.0/1.0 1.0/1.0 10
14 62 M Both Observation 1.0/1.0 1.0/1.0  2
15 56 M Both DM Observation 1.0/1.0 1.0/1.0  2
16 70 M Both HTN Observation 1.0/1.0 1.0/1.0  2
VApre = visual acuity before treatment; VApost = visual acuity after treatment; LP = laser photocoagulation; DM = diabetes mellitus; 
HTN = hypertension; IVB = intravitreal bevacizumab injection; IVTA = intravitreal triamcinolone acetonide; PDT = photodynamic 
therapy.
(mean, 48.6 years) at presentation. Disease was unilateral in 
all cases, involving three right eyes and five left eyes. Two 
patients had diabetes mellitus. One had diabetes mellitus 
and hypertension. Six of the eight patients (75%) were treat-
ed for macular edema and were followed for 3 to 62 months 
(mean, 16.6 months). Two patients were treated by laser 
photocoagulation to the area of capillary leakage and the 
rest were treated by intravitreal bevacizumab and laser 
photocoagulation. However, at the last examination, visual 
acuity had improved in only one patient (case 9), visual 
acuity remained unchanged in three, and had worsened in 
two (Table 1).
The patient corresponding to case 12 was a 53-year-old 
man who presented with a complaint of decreased vision in 
his right eye 1 year previously. The BCVA in the right 
eye was 20 / 40. Fundus examination of the right eye 
showed significant macular edema and circinate exudates. 
Fundus fluorescein angiography revealed parafoveal 
telangiectasis. Optical coherence tomography (OCT) dem-
onstrated cystoid macular edema. He received two intra-
vitreal bevacizumab injections (1.25 mg in 0.05 mL) and one 
laser photocoagulation treatment. Three months later, visual 
acuity of his left eye remained unchanged and the macular 
edema in the right eye was not improved, as confirmed by 
OCT (Fig. 1).
Group 1B
 Two patients (one male and one female) were classified as 
group 1B. The patients were 55 and 59 years old at pre-
sentation and both had undergone treatment for macular ede-
ma (Table 1). In one patient (case 2), macular edema resolved 
after additional intravitreal trimacinolone acetonide (IVTA) 
injection; however, there was subsequent recurrence and the 
patient underwent vitrectomy. The other patient (case 6) was 
treated with PDT, and visual improvement and resolution of 
macular edema was achieved (Fig. 2).
Group 2A
 Six patients (four males and two females) were classified 
as group 2A. Patients ranged in age from 38 to 70 years 
(mean, 55.1 years) at presentation. Two patients had diabetes 
mellitus and one had systemic hypertension. Among them, 
one eye (case 8) was treated for macular edema with laser 
photocoagulation and PDT (Table 1). The visual acuity re-
mained unchanged. The remaining five patients did not re-
ceive treatment (Fig. 3).
Discussion
IJT is an uncommon retinal disorder characterized by in-
competent and dilated retinal capillaries in the foveal and 
parafoveal region. IJT was first described by Gass in 1968 
[13]. According to a revised classification [2], group 1A is 
unilateral congenital parafoveolar telangiectasis. This class 
is characterized by prominent telangiectatic retinal capil-
laries that typically involve the temporal half of the macula 
for 2 disc diameters (DD) or greater and are usually asso-
ciated with varying amounts of yellowish exudate. More than 
90% of patients with group 1A disease are males, with an 
average age of 39 years, and more than 90% are unilateral SW Lee, et al. Idiopathic Juxtafoveal Telangiectasis in Koreans
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Fig. 1. Group 1A idiopathic juxtafoveal retinal telangiectasis (case 12). (A) Color fundus photography of the left eye on 
presentation showed a lipid exudate with aneurysm-like capillaries in its center. (B) Fluorescein angiography of the left eye 
on presentation showed telangiectasis and microaneurysm. (C) Optical coherence tomography of the left eye on pre-
sentation indicates macular edema with foveolar detachment. (D) Macular edema showed no improvement 3 months after 
a repeat intravitreal bevacizumab treatment and focal laser photocoagulation. 
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A B
Fig. 2. Group 1B idiopathic juxtafoveal retinal telangiectasis (case 6). (A) Color fundus photography of the right eye on 
presentation. (B) Fluorescein angiography of the right eye on presentation showed focal juxtafoveal telangiectasis. (C) 
Optical coherence tomography of the right eye on presentation. Images demonstrated a foveal cystoid and intraretinal 
edema. (D) The macular edema resolved after photodynamic treatment.Korean J Ophthalmol Vol.25, No.4, 2011
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Fig. 3. Group 2A idiopathic juxtafoveal retinal telangiectasis (case 10) (A,B) Color fundus photography of both eyes on pre-
sentation showed slight graying of the perifoveal retina and lipid exudates in the right eye. (C,D) Fluorescein angiography 
of both eyes on presentation showed telangiectatic change in the temporal macular lesion.
cases. In our study, 75% of the patients were male with a 
mean age of 48.6 years and all were unilateral. Decreased 
visual acuity was most commonly caused by macular edema, 
which was present in 6 of 8 patients. Tripathi and Ashton [14] 
suggested that the cause of telangiectasis in group 1A is a 
functional or structural breakdown of the blood-retinal bar-
rier (vascular endothelial) with consequent mural disorganiza-
tion and formation of aneurysms or telangiectasis. Group 1B 
patients also show male predilection and unilaterality. 
Lesions are visible, exudative, and focal juxtafoveolar te-
langiectasis with a small focal area of incompetent capil-
laries next to the foveal avascular zone. We observed these 
lesions in only two of our study patients.
Group 2A is characterized by bilaterality, and occult and 
nonexudative acquired parafoveolar telangiectasis that is of-
ten located temporal to the fovea, with a more or less sym-
metric appearance in both eyes. There is no gender predi-
lection and 95% of patients have bilateral involvement at ini-
tial presentation. In our series, the median age was 55.1 
years, which was similar to the mean age of 55 years in the 
Gass-Blodi series, and men were more frequently affected 
than woman (66.7%). 
Group 2B is juvenile occult familial IJT. Group 3A repre-
sents occlusive IJT with visual loss, minimal exudation, and 
extensive occlusion of the juxtafoveal capillary network in 
both eyes. Group 3B is occlusive IJT associated with central 
nervous system vasculopathy.
 In prior studies, the most common subtype was group 2A, 
followed by group 1A [2,15-17]. In a previous report on 
Korean patients, Chang et al. [3] reported that group 1B was 
the most common, whereas group 1A was most the common 
subtype in our study. These differences can be attributed to 
different classifications. Chang et al. [3] added the classi-
fication that there is no lipid exudation in group 1B even if te-
langiectatic retinal capillaries involved the macula for 2DD 
or greater. However, Gass and Blodi [2] proposed that group 
1B is a mild form of the disease seen in group 1A patients, 
and Yannuzzi et al. [17] considered that group 1B progresses 
to a more extensive disease with time and therefore group 1A 
and 1B should be merged by omitting the distinctions based 
on two clock hours of involvement in the juxtafoveal area. In 
the results of Chang et al. [3] and our study, group 1 disease 
was more common than group 2 among Korean IJT patients, 
in contrast to findings of the largest two previous series [2,1
7]. This difference may be partly due to limitations of our 
study. The significance of our study was limited by the small 
number of cases and the possibility that there were many 
asymptomatic patients who did not visit hospital. In recent 
large-scaled epidemiological studies [18,19], the prevalence 
of macular telangiectasis type 2 was higher than previously 
believed because early cases, which are usually asympto-
matic, go undetected.SW Lee, et al. Idiopathic Juxtafoveal Telangiectasis in Koreans
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Diabetes mellitus has been reported as a risk factor for IJT 
[20]. One report also described a high incidence of impaired 
glucose tolerance in these patients [21]. Although we had 
five patients with diabetes mellitus at the time of presentation, 
it was difficult to prove or disprove a correlation between 
diabetes and IJT.
 The cause of vision loss in patients with IJT is macular 
edema and hard exudates in group 1, and foveal atrophy or 
choroidal neovascularization in group 2 [2,16,17]. Therapeutic 
options for IJT are limited. Macular laser photocoagulation 
has been proposed for all forms of IJT by several authors; 
however, it was reported that treatment was helpful only for 
group 1 but not for group 2, and success was confined to 
cases in which the ectatic vessels were not close to the fo-
veal center [2,4]. A few case reports support the use of PDT 
for IJT with macular edema or choroidal neovascularization 
[5,6]. Two cases in our study were treated by PDT: one was 
group 1B IJT with macular edema and the other was group 
2A IJT with subretinal neovascularization. At the last fol-
low up, macular edema was improved in the former and 
subretinal neovascularization remained quiescent in the 
latter. Several recent case studies have demonstrated the 
safety and potential benefits of intravitreal anti-angiogenic 
[10,11,22,23] and steroid drugs [7,8], providing new possi-
bilities for the stabilization of vessel walls and reduction of 
fluid leakage and edema. 
In this study, nine eyes with macular edema underwent 
treatment; six eyes in group 1A, two in group 1B, and one in 
group 2A. Macular edema showed improvement in eight of 
the nine eyes, whereas visual acuity increased in only two 
eyes; one in group 1B that underwent PDT (case 6) and one 
in group 1A that was refractory to laser photocoagulation and 
underwent additional intravitreal bevacizumab injection 
therapy (case 9). Five eyes did not show visual improvement 
and two eyes presented with aggravated vision. Four cases of 
macular edema in group 1A IJT were refractory to laser pho-
tocoagulation and were treated with intravitreal injection of 
bevacizumab. None of them showed improvement of visual 
acuity (Table 1). In the study of Gass and Blodi [2], there 
were only five patients in group 1B and the prognosis for 
these patients was favorable. Only one of them was treated 
by laser photocoagulation because of a decline in visual acui-
ty, which returned to 20 / 20 after treatment. In contrast, both 
group 1B patients in our study were treated because visual 
acuities decreased below 20 / 40. The patient who was treat-
ed with IVTA developed cataract after treatment. Although 
the patient had cataract surgery, there was recurrence of mac-
ular edema. The patient underwent vitrectomy and laser pho-
tocoagulation; however, the visual acuity worsened because 
of vascularized retinal scars.
 In summary, in our study, group 1A IJT was the most com-
mon, followed by group 2A. Macular edema was the most 
common cause of decreased vision in IJT; however, no treat-
ment modality showed consistent efficacy. Further inves-
tigation is obviously required to improve the treatment of 
macular edema in IJT patients.
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